Cancer-Leukemia-Acute Myeloid Leukemia
| Title: | A Phase III, Double-Blind, Placebo-Controlled, Multicenter, Randomized Study Of Pracinostat In Combination With Azacitidine In Patients ≥18 Years With Newly Diagnosed Acute Myeloid Leukemia Unfit For Standard Induction Chemotherapy |
| Description: | This is a Phase III, multicenter, double-blind, randomized study of pracinostat vs. placebo with azacitidine (AZA) as background therapy in patients ≥ 18 years of age with newly diagnosed acute myeloid leukemia (AML), excluding acute promyelocytic leukemia and cytogenetic low-risk AML, who are unfit to receive intensive remission induction chemotherapy due to age ≥ 75 years or comorbidities. |
| Drug/Procedure: | Pracinostat; Azacitidine |
| NCT Number: | 03151408 |
| Notes: | Phase 3 |
| Start Date: | 12/4/17 |
| Status: | Recruiting |
| Principal Name: | Alan Langerak, MD |
| Contact Name: | Olga Bittner, CCRC |
| Phone: | (208) 367-7954 |